Aware Super Pty Ltd as trustee of Aware Super Invests $91.44 Million in Eli Lilly and Company $LLY

Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 99,418 shares of the company’s stock, valued at approximately $91,442,000. Eli Lilly and Company makes up about 1.4% of Aware Super Pty Ltd as trustee of Aware Super’s portfolio, making the stock its 10th biggest holding.

A number of other hedge funds have also added to or reduced their stakes in LLY. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares in the last quarter. State Street Corp grew its holdings in Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after buying an additional 635,358 shares in the last quarter. Morgan Stanley grew its holdings in Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares in the last quarter. Capital World Investors raised its position in Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Eli Lilly and Company by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after buying an additional 1,432,069 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley strengthens its neuroscience pipeline and adds exposure to treatment-resistant depression and other mental health markets. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Several Wall Street notes also turned more bullish on Lilly, with UBS and other firms raising price targets and pointing to continued momentum in Lilly’s GLP-1 and broader pipeline. Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says
• Neutral Sentiment: The acquisition comes amid mixed competitive headlines in obesity drugs, including Novo Nordisk’s oral Wegovy approval in Europe, which highlights the rivalry in Lilly’s core growth areas. Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions
• Negative Sentiment: Some commentary suggests Lilly is paying a rich price for a still-early-stage psychedelic asset, which may raise questions about clinical risk and return on investment if the programs do not deliver. Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion

Eli Lilly and Company Trading Up 1.4%

Shares of Eli Lilly and Company stock opened at $1,172.50 on Friday. The firm has a market cap of $1.10 trillion, a PE ratio of 41.65, a P/E/G ratio of 1.45 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a fifty day moving average price of $1,114.27 and a 200-day moving average price of $1,035.81.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 34.55 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LLY. Barclays lifted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. UBS Group increased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a report on Monday. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research report on Monday, June 22nd. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 1st. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.